

Index

- 5-alpha-reductase type 2 deficiency, 47, 139
- abdominal pain
 cyclical, 50–1, 146
- adverse incidents
 use of reflective practice, 43, 131
- amenorrhoea, 50–1, 146
- amniocentesis
 detection of chromosome anomalies, 56, 156
 risk of miscarriage, 21, 88–9
- amniotic fluid
 blood-stained, 59, 161–2
- anabolic steroids
 effects on male fertility, 48, 141–2
- androgen insensitivity syndrome, 47, 139
- antibiotics
 contraceptive failure caused by, 55–6, 155
- anti-c antibodies
 management in pregnancy, 51–2, 147–8
- anticoagulant prophylaxis, 13, 75
- anti-D antibodies
 management during pregnancy, 50, 145
- anti-D immunoglobulin for rhesus D
 prophylaxis, 10, 68–9
- anti-D prophylaxis
 indications for, 47–8, 139
- antidepressants
 antenatal and postnatal use, 23, 92–3
- antihypertensive agents, 15, 58, 79, 159
- anti-La antibodies, 11, 71–2
- antiphospholipid syndrome, 23, 93–4
- anti-Ro antibodies, 11, 71–2
- appraisal meetings, 42, 129–30
- appraisal process, 16, 80–1
- array comparative genomic hybridization
 (CGH), 56, 156
- aspirin treatment, 11, 70–1
- assessment methods, 16, 80–1
- assessment tools, 10, 69
- assisted reproduction
 bilateral hydrosalpinges, 9–10, 68
- asthma
- appropriate postpartum antihypertensive,
 58, 159
- deterioration in pregnancy, 42, 128
- exacerbations during pregnancy, 33,
 111–12
- medication during labour and postpartum,
 32, 110–11
- autoimmune disease, 11, 41, 71–2, 127
- autonomic dysreflexia
 risk in pregnant women with SCI, 52,
 148–9
- azoospermia
 and anabolic steroids, 48, 141–2
 cause in male with cystic fibrosis, 46, 136
 causes, 48, 141–2
- bacterial sepsis following pregnancy, 14, 15,
 30, 76, 78, 107–8
- causative organisms, 35, 115
- symptoms, 35, 115
- bacterial sepsis in pregnancy
 maternal mortality rate, 15–16, 79–80
 risk of maternal mortality, 34, 114
- bipolar disorder
 risk of postpartum psychosis, 25, 97
- bleeding disorders, 24, 94–5
- blood tests
 liver function tests, 18, 84
- blood transfusion
 blood type for pregnant women, 41, 127–8
 management during pregnancy, 41, 127–8
- BRCA mutations
 ovarian and breast cancer risks, 26, 99
- breech presentation
 external cephalic version (ECV), 50, 144
 rate of spontaneous version, 50, 144
- caesarean section, 12, 73
- nerve injury associated with, 33, 112
- risk of massive obstetric haemorrhage, 48,
 140
- cardiotocography, 59, 162

Cambridge University Press

978-1-107-47960-9 - SBA Questions for the Part 2 MRCOG: The Part 2 MRCOG SBA Question Writing Group

Edited by Amanda Jones FRCOG

Index

[More information](#)

Index

- cardiovascular system
 - changes in pregnancy, 17, 82–3
- cervical cerclage, 12, 73
 - indications for, 40, 126
- cervical cytopathology
 - management, 35, 116
- cervical intraepithelial neoplasia (CIN), 10, 69–70
 - incomplete excision, 19–20, 25, 86, 98
- cervical smear
 - frequency after CIN excision, 25, 98
 - frequency for HIV-positive patient, 22, 92
- cervix
 - premalignant disease, 55, 154
 - transformation zone, 55, 154
- chickenpox
 - exposure during pregnancy, 23, 31, 53, 94, 109, 150
- Chlamydia trachomatis*
 - neonatal infections, 43, 130
- Chlamydia* treatment, 12, 72–3
- chorioamnionitis
 - diagnosis, 59, 162
- chromosome anomalies
 - detection of, 56, 156
- chronic kidney disease
 - risk of pre-eclampsia, 37, 119
- coagulation system
 - changes in pregnancy, 17, 82–3
- congenital adrenal hyperplasia, 47, 139
- congenital bilateral absence of the vas deferens (CBAVD), 46, 136
- contraception
 - and treatment for *Chlamydia*, 12, 72–3
 - drug interactions with hormonal contraception, 55–6, 155
 - emergency, 12, 28, 72–3, 103–4
 - levonorgestrel-releasing intrauterine system, 44, 133
 - long-term, 44, 133
 - missed pill recommendations, 9, 67
 - time interval after delivery, 44, 133
 - VTE risk with combined oral contraceptives, 46, 137
- contraceptives
 - cervical cap with spermicide, 46, 136
 - medical eligibility classification, 30, 106–7
- cyclical abdominal pain, 50–1, 146
- cystic fibrosis
 - azoospermia in male partner, 46, 136–7
 - pattern of inheritance, 29, 36–7, 104
- cytomegalovirus (CMV) infection
 - risk of vertical transmission, 52, 149
- delivery
 - indications for operative delivery, 53, 150–1
- depression
 - antidepressant use in pregnancy, 23, 92–3
 - risk of postpartum psychosis, 25, 97
- dermatographia artefacta, 52–3, 149–50
- diabetes
 - risk factors, 11, 70–1
 - screening, 11, 70–1
 - See also* gestational diabetes
- drug interactions with hormonal contraception, 55–6, 155
- early fetal demise management, 26, 100
- early-onset neonatal group B streptococcal disease
 - prevention of, 45, 48, 49, 53, 134, 140, 143–4, 150
- eclampsia, 41, 127
- ectopic pregnancy, 17–18, 47–8, 83–4, 139
- emergency contraception, 9, 12, 67, 72–83
 - drug combinations, 28, 103–4
- endometrial polyps
 - diagnosis, 13, 74–5
- enhanced recovery in gynaecology, 16, 81
- epilepsy
 - management during pregnancy, 42, 128–9
 - risk of peripartum seizures, 42, 128–9
- external cephalic version (ECV), 50, 144
- face presentation
 - engaging diameter, 27–8, 102
 - head delivery, 28, 103
- faecal incontinence, 13, 75–6
- faecal urgency
 - following perineal tear, 37–8, 120–1
- female genital mutilation (FGM), 9, 67–8
- femoral nerve
 - injury associated with hysterectomy, 11–12, 14, 31, 57, 72, 76–7, 108–9, 158–9
- fertility assessment, 10–11, 70
- fetal bleeding, 59, 161–2
- fetal heart pattern
 - sinusoidal trace, 59, 161–2
- fetal hydrops. *See* hydrops fetalis
- fetal infections
 - prenatal diagnosis and management, 52, 149
- fetal loss
 - listeriosis, 39, 123
- fetal mortality rate
 - in non-immune hydrops fetalis, 42, 129
- fetal movements
 - reduced, 19, 47, 85–6, 138
- fetomaternal haemorrhage (FMH), 10, 68–9
- fetus
 - congenital heart block risk, 29, 105
 - heart block related to autoimmune disease, 11, 41, 71–2, 127
 - shoulder dystocia, 48, 141
 - small for gestational age, 41, 126
- fibroids, 11–12, 31, 40, 72, 108–9, 125–6
- uterine artery embolization (UAE), 22, 91
- genetic testing
 - following third miscarriage, 18, 84
 - recurrent miscarriage, 27, 101
- gestational diabetes, 11, 70–1
 - diagnostic criteria, 56, 156–7
- gestational trophoblastic disease, 28, 102–3
 - follow-up, 33, 113
 - partial moles, 43–4, 132
- gestational trophoblastic neoplasia (GTN)
 - management, 33, 113
- group A streptococcal (GAS) disease
 - necrotizing fasciitis, 58–9, 160–1
 - puerperal sepsis, 58–9, 159–61
- group B streptococcal (GBS) disease
 - prevention of early-onset neonatal infection, 48, 49, 140, 143–4

Cambridge University Press

978-1-107-47960-9 - SBA Questions for the Part 2 MRCOG: The Part 2 MRCOG SBA Question Writing Group

Edited by Amanda Jones FRCOG

Index

[More information](#)

- haematological changes during pregnancy, 25, 96–7
- haemolytic disease of the newborn, 51–2, 147–8
- head delivery
 - in a face presentation, 28, 103
- HELLP syndrome, 41, 127
- heparin
 - venous thrombosis prophylaxis, 12–13, 74
- history-taking assessment, 10, 69
- HIV infection in pregnancy
 - effectiveness of HAART, 32, 111
 - labour and delivery, 58, 160
 - management, 11, 58, 71, 160
 - management of labour, 57, 157–8
 - reduction of mother to child transmission, 32, 111
 - risk of vertical transmission, 39–40, 124
- HIV-positive patient
 - frequency of cervical smears, 22, 92
- human papilloma virus (HPV)
 - type responsible for vaginal disease, 32, 110
- hydrops fetalis, 14, 77
- hydrops fetalis (non-immune)
 - fetal mortality rate, 42, 129
- hydrosalpinges, 9–10, 68
- hyperandrogenism
 - differential diagnosis, 56, 155–6
- hypertension
 - postpartum, 15, 79
- hypertension in pregnancy, 22, 41, 90–1, 127
 - See also* pre-eclampsia
- hypogonadotropic hypogonadism in males, 48, 141–2
- hysterectomy, 10, 40, 69–70, 125–6
 - nerve injury associated with, 11–12, 14, 31, 51, 57, 72, 76–7, 108–9, 146–7, 158–9
 - vaginal vault prolapse, 59, 161
- hysteroscopes, 15, 78–9
- hysteroscopy
 - pain control, 20, 88
 - reducing procedure-related pain, 40, 124–5
 - uterine perforation, 21, 89–90
- ilioinguinal nerve
 - injury associated with hysterectomy, 51, 146–7
- imperforate hymen, 50–1, 146
- induction of labour, 19, 85–6
- infanticide, 25, 97
- infections
 - risk of vertical transmission, 52, 149
- infertility
 - assessment of male infertility, 48, 141–2
 - azoospermia in male with cystic fibrosis, 46, 136
 - bilateral hydrosalpinges, 9–10, 68
 - congenital bilateral absence of the vas deferens (CBAVD), 46, 136
 - effects of male anabolic steroid use, 48, 141–2
 - male hypogonadotropic hypogonadism, 48, 141–2
 - treatments, 10–11, 70
 - unexplained, 10–11, 70
- inherited bleeding disorders, 24, 94–5
- intrapartum pyrexia
 - risk of early-onset neonatal group B streptococcal disease, 45, 134
- itching in pregnancy, 52–3, 149–50
- IVF treatment, 10–11, 70
 - bilateral hydrosalpinges, 9–10, 68
- karyotyping, 18, 84
- labour
 - active management of third stage, 53–4, 151
 - continuous support during, 24, 96
 - diagnosis of delay in first stage, 38, 121–2
 - indications for operative delivery, 53, 150–1
 - induced, 19, 85–6
 - management of delay in first stage, 38, 121–2
 - prolonged third stage, 47, 138
- laparoscopic surgery
 - ureteric injury associated with, 34–5, 115
- laparoscopy
 - avoiding entry-related injuries, 31, 43, 109–10, 131–2
 - intra-abdominal pressure, 21, 43, 89, 131–2
- levonorgestrel-releasing intrauterine contraceptive system, 44, 133
- lidocaine
 - dosage, 16, 80
 - toxicity symptoms, 16, 80
- listeriosis
 - and preterm fetal loss, 39, 123
- liver function tests, 18, 84
- local anaesthetic
 - lidocaine dosage, 16, 80
- low-molecular-weight heparin (LMWH), 12–13, 74
- magnesium toxicity
 - signs of, 45–6, 135–6
- malaria in pregnancy, 35–6, 116–17
- male infertility
 - assessment of, 48, 141–2
 - effects of anabolic steroids, 48, 141–2
- malpresentation, 28, 103
- massive obstetric haemorrhage
 - risk with placenta praevia, 48, 140
- maternal morbidity
 - risk factors, 12, 73–4
- maternal mortality
 - direct and indirect causes, 25, 97–8
 - impact of obesity, 49, 142–3
 - postpartum psychosis, 25, 97
 - rate in severe sepsis, 15–16, 79–80
 - risk factors, 12, 73–4
 - risk in bacterial sepsis, 34, 114
 - risk in septic shock, 34, 114
 - sepsis mortality risk factors, 17, 83
 - suicide, 25, 97
- Mayer–Rokitansky–Küster–Hauser (MRKH) syndrome, 47, 139
- McRoberts' manoeuvre
 - teaching, 48, 141
- membrane rupture. *See* rupture of membranes
- mifepristone dosage, 26, 100
- mini-CEX (mini clinical evaluation exercise), 10, 69

Cambridge University Press

978-1-107-47960-9 - SBA Questions for the Part 2 MRCOG: The Part 2 MRCOG SBA Question Writing Group

Edited by Amanda Jones FRCOG

Index

[More information](#)

Index

- miscarriage
 - antiphospholipid syndrome, 23, 93–4
 - cause of recurrent miscarriage, 23, 93–4
 - causes of first-trimester miscarriage, 44, 133
 - diagnosis in early pregnancy, 17–18, 83–4
 - genetic testing, 18, 27, 84, 101
 - incomplete, 27, 101
 - indications for anti-D prophylaxis, 47–8, 139
 - investigating recurrent first-trimester miscarriages, 45, 134–5
 - management of future pregnancy, 46–7, 137
 - prevention of recurrent unexplained miscarriage, 49, 142
 - recurrent, 26–7, 36, 100, 101, 118
 - risk following three consecutive miscarriages, 36, 118
 - risk of further miscarriages, 49, 142
 - risk with amniocentesis, 21, 88–9
- misoprostol dosage, 26, 100
- missed pill recommendations, 9, 67
- molar pregnancy, 28, 102–3
 - chromosomal composition of partial moles, 43–4, 132
- monochorionic twin pregnancy, 20, 87
- multiparous women
 - reducing the risk of postpartum haemorrhage, 53–4, 151
- myasthenia gravis
 - drugs to avoid in pregnancy, 39, 123–4
- necrotizing fasciitis
 - diagnosis and management, 58–9, 160–1
- neonatal chlamydial infections, 43, 130
- neonatal conjunctivitis
 - causative organisms, 43, 130
- neonatal resuscitation training, 56–7, 157
- neonatal varicella infection, 44–5, 133–4
- nerve injury
 - associated with caesarean section, 33, 112
 - associated with hysterectomy, 11–12, 14, 31, 51, 57, 72, 76–7, 108–9, 146–7, 158–9
 - associated with sacrospinous fixation, 36, 117
 - indications of obturator nerve injury, 38–9, 122
- nocturia
 - management options, 38, 121
 - treatment for frail older patients, 51, 147
- obesity
 - and polycystic ovarian syndrome, 51, 146
 - impact on pregnant women, 49, 142–3
 - maternal sepsis mortality risk, 17, 83
 - risk of maternal morbidity and mortality, 12, 73–4
- obstetric cholestasis
 - itching associated with, 52–3, 149–50
- obturator nerve injury
 - motor findings, 38–9, 122
- occipito-posterior presentation, 28, 103
- oral contraceptive pill
 - contraindications, 30, 106–7
- oral glucose tolerance test (OGTT), 56, 156–7
- outpatient diagnostic hysteroscopy
 - pain control, 20, 88
- ovarian cancer
 - five-year survival, 37, 119–20
 - staging, 37, 119–20
- ovarian cancer risk
 - and *BRCA* mutations, 26, 99
 - lifetime risk in the general population, 27, 101
- ovarian cysts
 - in postmenopausal women, 40, 125
 - in premenopausal women, 20, 86–7
 - management, 29, 104–5
 - management of simple small cysts, 54–5, 153
 - surgical management, 40, 125
- ovarian masses
 - management, 29, 30, 104, 106
- ovarian torsion
 - diagnosis and management, 30, 107
- ovarian tumour markers, 30, 106
- overactive bladder, 21, 90
 - management options, 38, 121
 - treatment, 23, 93
 - treatment for frail older patients, 51, 147
- pain
 - diagnosis of pudendal neuralgia, 54, 153
- partial moles
 - chromosomal composition, 43–4, 132
- parvovirus infection in pregnancy, 14, 77
- pelvic fracture
 - pregnant patient, 31, 108
- perineal tears, 13, 22, 75–6, 91–2
 - classification, 43, 130–1
 - faecal urgency following, 37–8, 120–1
 - outcome following primary repair, 37–8, 120–1
- periods
 - infrequent, 51, 146
- persistent trophoblast, 18–19, 85
- personal development plan, 42, 129–30
- placenta
 - prolonged third stage of labour, 47, 138
- placenta praevia
 - risk of massive obstetric haemorrhage, 48, 140
- placental abruption
 - risk in a subsequent pregnancy, 24, 95–6
- polycystic ovary syndrome, 51, 146
 - differential diagnosis, 56, 155–6
- polymorphic eruption of pregnancy, 26, 99–100
- POPQ scoring system
 - vaginal vault, 59, 161
- postmenopausal vulval itching, 44, 132
- postnatal fever and rigor, 58–9, 159–61
- postpartum depression, 25, 97
- postpartum haemorrhage
 - reducing the risk of, 53–4, 151
- postpartum hypertension, 15, 79
 - antihypertensive for asthmatic patient, 58, 159
- postpartum psychosis
 - risk factors, 25, 97
- pre-conception counselling
 - antidepressant use in pregnancy, 23, 92–3
 - risk of postpartum psychosis, 25, 97
- pre-eclampsia
 - management, 37, 120

Cambridge University Press

978-1-107-47960-9 - SBA Questions for the Part 2 MRCOG: The Part 2 MRCOG SBA Question Writing Group

Edited by Amanda Jones FRCOG

Index

[More information](#)

- risk factors, 37, 119
 - risk in subsequent pregnancies, 41, 49, 127, 143
 - risk of recurrence, 22, 90–1
 - signs of magnesium toxicity, 45–6, 135–6
- presenting diameter, 28, 103
- professional development needs
 - use of reflective practice, 43, 131
- progestogens
 - VTE risk in combined oral contraceptives, 46, 137
- pruritis in pregnancy, 26, 52–3, 99–100, 149–50
- pudendal nerve
 - injury associated with sacrospinous fixation, 36, 117
 - three branches, 55, 154–5
- pudendal nerve block, 55, 154–5
- pudendal neuralgia
 - diagnosis, 54, 153
- puerperal sepsis, 14, 76
 - diagnosis and management, 58, 159–60
 - group A streptococcal (GAS) disease, 58–9, 160–1
- recurrent urinary tract infections (UTIs), 50, 145
- reduced fetal movements, 19, 47, 85–6, 138
- reflective practice, 43, 131
- relative risk
 - explanation of, 54, 152
- resuscitation training, 56–7, 157
- retained products of conception
 - risks associated with surgical evacuation, 45, 135
- rhesus D prophylaxis, 10, 68–9
- risk
 - explanation of relative risk, 54, 152
 - ways to explain, 20, 87–8
- rupture of membranes
 - preterm pre-labour rupture, 49, 59, 143–4, 162
- sacrospinous fixation
 - nerve injury associated with, 36, 117
- salpingectomy, 18–19, 85
- salpingostomy, 18–19, 85
- sepsis
 - diagnosis and management, 58, 159–60
 - group A streptococcal (GAS) disease, 58–9, 160–1
 - group A streptococcal (GAS) puerperal sepsis, 58, 159–60
 - risk factors for maternal mortality, 17, 83
- septic shock, 30, 107–8
 - risk of maternal mortality, 34, 114
- severe maternal sepsis, 15, 30, 78, 107–8
 - mortality rate, 15–16, 79–80
 - risk factors, 12, 73–4
- shoulder dystocia, 14–15, 48, 77–8, 141
- sickle cell disease
 - management in pregnancy, 33, 112–13
 - pattern of inheritance, 33, 112–13
- sickle cell trait
 - pattern of inheritance, 33, 112–13
- simple ovarian cyst
 - management, 29, 104–5
- simulation training, 14–15, 77–8
- Sjögren's syndrome antibodies, 11, 71–2
- skills development
 - simulation training, 14–15, 77–8
- skin conditions in pregnancy, 26, 52–3, 99–100, 149–50
- slapped cheek syndrome in pregnancy, 14, 77
- spinal cord injury (SCI)
 - pregnancy care plan, 52, 148–9
 - risks associated with pregnancy, 52, 148–9
- spontaneous vaginal delivery
 - influential factors, 24, 96
- statistical tests, 35, 115–16
- suicide (maternal), 25, 97
- surgery
 - instruments causing uterine perforation, 32, 110
 - nerve injury associated with, 11–12, 14, 31, 36, 51, 57, 72, 76–7, 108–9, 117, 146–7, 158–9
 - sites of uterine perforation, 34, 114
 - ureteric injury associated with, 34–5, 115
 - WHO surgical sign out, 16–17, 81–2
- suture absorption
 - time taken, 55, 154
- suture materials
 - appropriate choice of, 55, 154
- Swyer's syndrome, 47, 139
- systemic lupus erythematosus (SLE)
 - in pregnancy, 11, 41, 71–2, 127
 - maternal and fetal complications, 29, 105
- teaching methods
 - simulation training, 14–15, 77–8
- teratogenic drugs, 39, 123–4
- testosterone
 - raised serum levels in women, 56, 155–6
- thalassaemia
 - cardiac iron overload, 36, 117–18
 - management in pregnancy, 29, 36, 105–6, 117–18
- thrombophilia screening, 25, 39, 96–7, 122–3
- transformation zone of the cervix, 55, 154
- truncus arteriosus
 - detection of cause, 56, 156
- tubal pregnancy, 18–19, 85
- tumour markers
 - ovarian tumours, 30, 106
- twins
 - management of delivery, 57, 158
 - monochorionic twin pregnancy, 20, 50, 87, 144–5
 - prognosis following single-twin death, 50, 144–5
- umbilical artery Doppler, 41, 126
- unexplained infertility, 10–11, 70
- ureters
 - injury associated with surgery, 34–5, 115
- urinary frequency
 - management options, 38, 121
- urinary incontinence, 21, 90
 - treatment for frail older patients, 51, 147
- urinary tract infection (UTI)
 - recurrent infections, 50, 145
- urinary urgency
 - management options, 38, 121
 - treatment for frail older patients, 51, 147

Index

- uterine artery embolization (UAE), 22, 91
- uterine inversion, 26, 98–9
- uterine perforation
 - during hysteroscopy, 21, 89–90
 - instruments causing, 32, 110
 - most common sites, 34, 114
 - procedures associated with risk of, 54, 152
 - risk in postpartum procedures, 45, 135
- utero-vaginal prolapse, 50, 145
- vagina
 - congenital abnormalities, 47, 139
- vaginal carcinoma
 - HPV type responsible, 32, 110
- vaginal delivery
 - influential factors in spontaneous delivery, 24, 96
- vaginal vault cytology, 10, 40, 69–70, 125–6
- vaginal vault on POPQ scoring system, 59, 161
- vaginal vault prolapse, 59, 161
 - frail elderly patient, 38, 122
 - indications for colpocleisis, 38, 122
- varicella-zoster virus
 - infection in pregnancy, 23, 31, 44–5, 94, 109, 133–4
- vasa praevia, 59, 161–2
 - diagnosis and management, 34, 113–14
- venous thromboembolism (VTE)
 - incidence in pregnancy and the puerperium, 24, 95
 - prophylaxis, 12–13, 74, 75
 - risk factors, 13, 75
 - risk in pregnancy, 17, 82–3
 - risk in pregnant patients with thalassaemia, 29, 105–6
 - risk of heritable thrombophilia, 39, 122–3
 - risk with combined oral contraceptives, 46, 137
 - thrombophilia screen, 39, 122–3
- viral rash in pregnancy, 14, 77
- von Willebrand’s disease, 24, 94–5
- vulva
 - lesion treatment, 22–3, 92
 - pain and itching, 27, 101–2
 - postmenopausal itching, 44, 132
- vulval dermatitis, 27, 101–2